CY1117414T1 - Παραγοντες αναστροφης αντιπηκτικου - Google Patents

Παραγοντες αναστροφης αντιπηκτικου

Info

Publication number
CY1117414T1
CY1117414T1 CY20161100338T CY161100338T CY1117414T1 CY 1117414 T1 CY1117414 T1 CY 1117414T1 CY 20161100338 T CY20161100338 T CY 20161100338T CY 161100338 T CY161100338 T CY 161100338T CY 1117414 T1 CY1117414 T1 CY 1117414T1
Authority
CY
Cyprus
Prior art keywords
compounds
refrigerator
factors
reverse
methods
Prior art date
Application number
CY20161100338T
Other languages
English (en)
Inventor
Solomon S Steiner
Bryan E Laulicht
Sasha H Bakhru
Edith Mathiowitz
Original Assignee
Perosphere, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perosphere, Inc. filed Critical Perosphere, Inc.
Publication of CY1117414T1 publication Critical patent/CY1117414T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Abstract

Αποκαλύπτονται νέες ενώσεις αναστροφής αντιπηκτικού, καθώς επίσης μέθοδοι κατασκευής των ενώσεων, φαρμακευτικές συνθέσεις που συμπεριλαμβάνουν τις ενώσεις, μέθοδοι χρήσης των ενώσεων για αναστροφή των αντιπηκτικών αποτελεσμάτων αναστολέων πήξης και διαγνωστικές δοκιμασίες που περιλαμβάνουν τις ενώσεις.
CY20161100338T 2011-11-29 2016-04-25 Παραγοντες αναστροφης αντιπηκτικου CY1117414T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161564559P 2011-11-29 2011-11-29
US201261614292P 2012-03-22 2012-03-22
US201261641698P 2012-05-02 2012-05-02
US201261666291P 2012-06-29 2012-06-29
EP12806229.6A EP2785700B1 (en) 2011-11-29 2012-11-29 Anticoagulant reversal agents

Publications (1)

Publication Number Publication Date
CY1117414T1 true CY1117414T1 (el) 2017-04-26

Family

ID=47430065

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100338T CY1117414T1 (el) 2011-11-29 2016-04-25 Παραγοντες αναστροφης αντιπηκτικου

Country Status (35)

Country Link
US (4) US9522892B2 (el)
EP (1) EP2785700B1 (el)
JP (1) JP6134731B2 (el)
KR (1) KR101892330B1 (el)
CN (1) CN104080772B (el)
AP (1) AP2014007662A0 (el)
AR (1) AR089020A1 (el)
AU (1) AU2012345975B2 (el)
BR (1) BR112014012892B1 (el)
CA (1) CA2856540C (el)
CL (1) CL2014001399A1 (el)
CO (1) CO6990738A2 (el)
CR (1) CR20140310A (el)
CY (1) CY1117414T1 (el)
DK (1) DK2785700T3 (el)
EA (1) EA027603B1 (el)
EC (1) ECSP14006696A (el)
ES (1) ES2569674T3 (el)
HK (1) HK1202858A1 (el)
HR (1) HRP20160513T1 (el)
HU (1) HUE027452T2 (el)
IL (1) IL232788B (el)
ME (1) ME02424B (el)
MX (1) MX349514B (el)
PE (1) PE20141295A1 (el)
PH (1) PH12014501176B1 (el)
PL (1) PL2785700T3 (el)
PT (1) PT2785700E (el)
RS (1) RS54738B1 (el)
SG (1) SG11201402713WA (el)
SI (1) SI2785700T1 (el)
SM (1) SMT201600161B (el)
UA (1) UA116336C2 (el)
WO (1) WO2013082210A1 (el)
ZA (1) ZA201404793B (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015069844A1 (en) * 2013-11-08 2015-05-14 Perosphere Inc. Labeled compounds and methods of imaging, diagnosing cartilage disorders and diseases, and monitoring cartilage health using labeled and unlabeled compounds
AU2018365257B2 (en) * 2017-11-13 2021-05-13 Maximum Fidelity Surgical Simulations, LLC Reconstitution of post mortem circulation, specialized methods and procedures
JP2021529765A (ja) 2018-06-29 2021-11-04 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ａｘｌ／ｍｅｒ阻害剤の製剤
US11716989B2 (en) 2019-04-16 2023-08-08 Maximum Fidelity Surgical Simulations, LLC Cadaver preservation systems and methods
US11915610B2 (en) 2019-05-15 2024-02-27 Maximum Fidelity Surgical Simulations, LLC Cadaverous heart model
CN112010930B (zh) * 2019-05-28 2022-08-02 首都医科大学 Rgd修饰的五环哌嗪二酮及其制备和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3678157A (en) * 1968-10-23 1972-07-18 Oreal Hair treatment compositions containing polycondensable compounds
IL115420A0 (en) * 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
US6069232A (en) * 1995-10-02 2000-05-30 Hoechst Marion Roussel, Inc. Polyfluoroalkyl tryptophan tripeptide thrombin inhibitors
US6080852A (en) 1996-06-27 2000-06-27 The Perkin-Elmer Corporation 4,7-dichlororhodamine dyes
CA2268381A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
SI20115A (sl) * 1997-04-07 2000-06-30 Axys Pharmaceuticals, Inc. Spojine in sestavki za zdravljenje bolezni, povezanih z aktivnostjo serinskih proteaz, zlasti triptaze
FR2781221B1 (fr) * 1998-07-17 2000-10-13 Lafon Labor Piperazinones substituees en alpha
CA2348740A1 (en) * 1998-12-23 2000-07-06 Ruth R. Wexler Thrombin or factor xa inhibitors
CN1152023C (zh) 1999-05-19 2004-06-02 法玛西雅公司 作为抗凝血剂的取代的多环芳基与杂芳基尿嘧啶
CA2412345A1 (en) * 1999-06-16 2000-12-21 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
JP2004501077A (ja) 2000-04-17 2004-01-15 ファルマシア・コーポレーション 凝固カスケードの選択的阻害に有用な多環式アリールおよびヘテロアリール置換１，４−キノン
WO2002002519A2 (en) * 2000-06-29 2002-01-10 Bristol-Myers Squibb Pharma Company THROMBIN OR FACTOR Xa INHIBITORS
US6969715B2 (en) 2001-10-03 2005-11-29 Pharmacia Corporation 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
JP2005529860A (ja) 2002-03-27 2005-10-06 グラクソ　グループ　リミテッド ジアミノ酸−アミノ酸−ポリアミンに基づいたジェミニ界面活性剤化合物
EP1550455A1 (en) * 2002-05-23 2005-07-06 Chugai Seiyaku Kabushiki Kaisha Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation
GB0214122D0 (en) 2002-06-19 2002-07-31 Eastman Kodak Co High contrast photographic element containing a polyhydrazide nucleating agent
SE0400014D0 (sv) * 2004-01-08 2004-01-08 Astrazeneca Ab Heterocyclic derivatives
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
EP2915564B1 (en) * 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes for factor XA inhibitors and methods of using the same
GB2476643B (en) 2009-12-23 2012-11-14 Haomamedica Ltd 1,4-Dihydro-1,4-dioxonaphtalene derivatives as anticoagulants
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
MA34978B1 (fr) 2011-03-30 2014-03-01 Boehringer Ingelheim Int Antidotes pour anticoagulants

Also Published As

Publication number Publication date
US20170056396A1 (en) 2017-03-02
PT2785700E (pt) 2016-06-02
AU2012345975A1 (en) 2014-05-29
RS54738B1 (sr) 2016-10-31
CO6990738A2 (es) 2014-07-10
HK1202858A1 (en) 2015-10-09
ZA201404793B (en) 2015-04-29
SI2785700T1 (sl) 2016-09-30
JP2014534270A (ja) 2014-12-18
CL2014001399A1 (es) 2014-11-03
NZ625337A (en) 2016-11-25
BR112014012892A2 (pt) 2017-06-13
ES2569674T3 (es) 2016-05-12
BR112014012892A8 (pt) 2021-06-08
IL232788B (en) 2018-05-31
US9877961B2 (en) 2018-01-30
EA027603B1 (ru) 2017-08-31
MX2014006349A (es) 2014-09-04
SG11201402713WA (en) 2014-06-27
MX349514B (es) 2017-08-02
AP2014007662A0 (en) 2014-05-31
AR089020A1 (es) 2014-07-23
CN104080772A (zh) 2014-10-01
PE20141295A1 (es) 2014-10-01
KR20140107259A (ko) 2014-09-04
CA2856540C (en) 2018-04-03
SMT201600161B (it) 2016-07-01
CR20140310A (es) 2014-08-20
PH12014501176A1 (en) 2014-09-01
DK2785700T3 (en) 2016-06-13
HUE027452T2 (en) 2016-09-28
US9522892B2 (en) 2016-12-20
BR112014012892B1 (pt) 2022-12-20
PH12014501176B1 (en) 2014-09-01
CN104080772B (zh) 2016-10-05
US20130137702A1 (en) 2013-05-30
JP6134731B2 (ja) 2017-05-24
CA2856540A1 (en) 2013-06-06
US20210169874A1 (en) 2021-06-10
WO2013082210A1 (en) 2013-06-06
EP2785700A1 (en) 2014-10-08
PL2785700T3 (pl) 2016-09-30
AU2012345975B2 (en) 2016-12-15
ME02424B (me) 2016-09-20
HRP20160513T1 (hr) 2016-07-15
UA116336C2 (uk) 2018-03-12
ECSP14006696A (es) 2015-06-30
IL232788A0 (en) 2014-08-03
EA201490823A1 (ru) 2015-01-30
US20180207152A1 (en) 2018-07-26
KR101892330B1 (ko) 2018-08-27
EP2785700B1 (en) 2016-03-09

Similar Documents

Publication Publication Date Title
CY1117414T1 (el) Παραγοντες αναστροφης αντιπηκτικου
EA201591764A1 (ru) Варианты тканевого ингибитора металлопротеиназ третьего типа (timp-3), композиции и способы
EA201490826A1 (ru) Ингибиторы асс и их применения
EA201591961A1 (ru) Ингибиторы акк и их применение
EA201591959A1 (ru) Ингибиторы акк и их применение
EA201591960A1 (ru) Ингибиторы акк и их применение
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
CR20140275A (es) Triazolopiridinas sustituidas
UA111744C2 (uk) ЗАМІЩЕНІ ПІРИДОПІРАЗИНИ ЯК ІНГІБІТОРИ Syk
TR201909788T4 (tr) C4-monometil triterpenoid türevleri ve bunların kullanım yöntemleri.
EA201400579A1 (ru) Антитела к il-36r
CO2017011152A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx / ca.
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
EA201591962A1 (ru) Ингибиторы акк и их применение
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
EA201490846A1 (ru) Новые производные арилхинолина
EA201290642A1 (ru) Соединения и способы
BR112015032526A2 (pt) composições anticaspa e métodos de uso das mesmas
EA201590787A1 (ru) Замещенные пиридопиразины в качестве ингибиторов syk
CY1120395T1 (el) Παραγωγα στερολης και χρηση αυτων για την αγωγη νοσηματων που περιλαμβανουν μετασχηματισμενα αστροκυτταρα ή για την αγωγη κακοηθων αιμοπαθειων
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения
EA201590028A1 (ru) Ингибиторы гистондеацетилазы и их композиции и способы их применения
EA201692518A3 (ru) Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила
EA201691493A1 (ru) Замещенные n-арилпиридиноны